Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Bingbing Dai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2100-6415; OpenAlex author ID A5035770490. Sources: OpenAlex.

Their work

Papers
15 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: none · 2019: 3 papers · 2020: none · 2021: 4 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 15

  1. Editor's Note: Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-24-1527↗
  2. Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Co-author DOI 10.1038/s41419-021-03970-8↗
  3. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-20-3792↗
  4. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-20-1228↗
  5. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. Co-author DOI 10.1172/jci.insight.146133↗
  6. Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signa… First author DOI 10.1002/cam4.2581↗
  7. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models. Co-author DOI 10.1016/j.sopen.2019.05.004↗
  8. Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-018-0207-3↗
  9. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  10. Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth. Co-author DOI 10.1038/onc.2017.125↗
  11. Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarci… Co-author DOI 10.1158/1535-7163.mct-16-0526↗
  12. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition. Co-author DOI 10.1038/onc.2016.20↗
  13. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1078-0432.ccr-15-2780↗
  14. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-15-2936↗
  15. Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. First author DOI 10.7759/cureus.423↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jason B. Fleming · 15 shared papers, 2015–2024 · strength 1.37
  2. Ya’an Kang · 13 shared papers, 2016–2024 · strength 1.26
  3. Xinqun Li · 9 shared papers, 2016–2024 · strength 0.94
  4. David Roife · 8 shared papers, 2016–2024 · strength 0.77
  5. Mayrim V. Rios Perez · 8 shared papers, 2015–2024 · strength 0.73
  6. Michael P. Kim · 5 shared papers, 2019–2021 · strength 0.51
  7. Eugene Jon Koay · 6 shared papers, 2015–2021 · strength 0.49
  8. Jenying Deng · 3 shared papers, 2021 · strength 0.34
  9. Rolf A. Brekken · 3 shared papers, 2017–2021 · strength 0.28
  10. Timothy Paul Heffernan · 2 shared papers, 2021 · strength 0.20
  11. Matthew H. G. Katz · 2 shared papers, 2016–2021 · strength 0.17
  12. Yeon‐Ju Lee · 2 shared papers, 2016–2019 · strength 0.14
  13. Huocong Huang · 1 shared paper, 2021 · strength 0.12
  14. Alessandro Carugo · 1 shared paper, 2021 · strength 0.11
  15. Yan Liang · 1 shared paper, 2021 · strength 0.11
  16. Bo Tu · 1 shared paper, 2021 · strength 0.11
  17. Jun Yao · 1 shared paper, 2021 · strength 0.11
  18. Haoqiang Ying · 1 shared paper, 2021 · strength 0.11
  19. Wantong Yao · 1 shared paper, 2021 · strength 0.11
  20. Bin Liu · 1 shared paper, 2021 · strength 0.10
  21. Anirban Maitra · 1 shared paper, 2021 · strength 0.10
  22. Florencia M. McAllister · 1 shared paper, 2021 · strength 0.10
  23. Guillermina Lozano · 1 shared paper, 2021 · strength 0.10
  24. Fahmi Mesmar · 1 shared paper, 2019 · strength 0.08
  25. Cecilia Williams · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.